Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

In a Phase 1 trial led by Nina Bhardwaj, MD, PhD (Icahn School of Medicine at Mount Sinai), PGV001—a personalized neoantigen vaccine—kept 3 patients tumor-free for 5 years. Personalized vaccines like this may offer lasting protection. Learn more: www.mountsinai.org/about/newsro...

#PICInetwork

The mid-March issue of The Immuno-Oncology Digest has arrived! Discover exclusive insights on next-gen #CARTtherapies, innovative research tools and honors for leading investigators: mailchi.mp/parkerici/th...

#CancerResearch #Immunotherapy #PICInetwork